Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DCR STAT3

Next Previous
X
Search
Drug Profile

DCR STAT3

Alternative Names: DCR-STAT3; DCRSTAT3 - Dicerna Pharmaceuticals

Latest Information Update: 17 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dicerna Pharmaceuticals
  • Class Amides; Amino sugars; Antineoplastics; Drug conjugates; Small interfering RNA
  • Mechanism of Action RNA interference; STAT3 transcription factor expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 06 Nov 2023 DCR STAT3 is available for licensing as of 06 Nov 2023. https://dicerna.com/our-company/collaborating/
  • 14 Aug 2023 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (IV) (NCT06098651)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top